379 related articles for article (PubMed ID: 34497607)
1. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway.
Dang C; Lu Y; Chen X; Li Q
Front Immunol; 2021; 12():650708. PubMed ID: 33927721
[TBL] [Abstract][Full Text] [Related]
5. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Kubo S; Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
[No Abstract] [Full Text] [Related]
9. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
10. Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
Amer BE; Afifi E; Mouffokes A; Hamad AA; Amin AM; Abdelwahab OA
Clin Rheumatol; 2024 Feb; 43(2):579-589. PubMed ID: 37581759
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
12. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
[TBL] [Abstract][Full Text] [Related]
13. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
14. Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons.
Makabe K; Okada H; Tachibana N; Ishikura H; Ito N; Tanaka M; Chijimatsu R; Terashima A; Yano F; Asaka M; Yanagihara D; Taketomi S; Matsumoto T; Tanaka S; Omata Y; Saito T
Arthritis Res Ther; 2024 Jun; 26(1):121. PubMed ID: 38879555
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Dörner T; Tanaka Y; Petri MA; Smolen JS; Wallace DJ; Dow ER; Higgs RE; Rocha G; Crowe B; Benschop RJ; Byers NL; Silk ME; de Bono S; Fantini D; Hoffman RW
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33037080
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
[TBL] [Abstract][Full Text] [Related]
18. Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-κB pathway.
Yang L; Zhang T; Wang P; Chen W; Liu W; He X; Zhang Y; Jin S; Luo Z; Zhang Z; Wang X; Liu J
Cell Biol Toxicol; 2023 Dec; 39(6):3287-3304. PubMed ID: 37804401
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
Dörner T; van Vollenhoven RF; Doria A; Jia B; Ross Terres JA; Silk ME; de Bono S; Fischer P; Wallace DJ
Arthritis Res Ther; 2022 May; 24(1):112. PubMed ID: 35578304
[TBL] [Abstract][Full Text] [Related]
20. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
Front Immunol; 2020; 11():1047. PubMed ID: 32625200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
